ArticleThe American journal of pathology1996
Kaposi's sarcoma tumor cells preferentially express Bcl-xL.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 72 citations in OpenAlex.
- The role of apoptosis and its potential as a therapeutic target in inflammatory bowel disease associated with colorectal cancer.American journal of translational research · 2025Review
- Review
- Apoptotic cell signaling in cancer progression and therapy.Integrative biology : quantitative biosciences from nano to macro · 2011Review
- LANA-1, Bcl-2, Mcl-1 and HIF-1alpha protein expression in HIV-associated Kaposi sarcoma.Virchows Archiv : an international journal of pathology · 2009Article
- Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.Journal of cellular biochemistry · 2008Review
- Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.Bioorganic & medicinal chemistry · 2007Article
- Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells.Oncogene · 2005Article
- Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells.Journal of virology · 2003Article
- Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.The American journal of pathology · 2000Article
- Cyclin D1 expression and HHV8 in Kaposi sarcoma.Journal of clinical pathology · 1999Article
- CD40 upregulation is independent of HHV-8 in the pathogenesis of Kaposi's sarcoma.Molecular pathology : MP · 1999Article
- Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer.Annals of surgery · 1998Article
- Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies.Genes & development · 1998Article
- Human herpes virus 8 (HHV-8) in Kaposi's sarcoma: lack of association with Bcl-2 and p53 protein expression.Molecular pathology : MP · 1998Article
- Identification of HHV8 in early Kaposi's sarcoma: implications for Kaposi's sarcoma pathogenesis.Molecular pathology : MP · 1998Article
- Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.Pathology oncology research : POR · 1996Article
- Immunohistochemical Expression of Bcl-2, E-cadherin, CD34 and CD105 in Basaloid Squamous Cell Carcinoma - AnAnnals of maxillofacial surgeryArticle
- Killing of sarcoma cells by proapoptotic Bcl-X(S): role of the BH3 domain and regulation by Bcl-X(L).Neoplasia (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Several recently identified proteins such as Bcl-2 and Bcl-x have been found to regulate programmed cell death (i.e., apoptosis). In this report, we examined the levels of expression of proteins that can either prevent apoptosis (i.e., Bcl-2 or the long form of Bcl-x, designated Bcl-x1) or promote apoptosis (i.e., Bax or the short form of Bcl-x, designated Bcl-xs) in proliferating benign and malignant endothelial cells (ECs). In normal skin with quiescent ECs, no detection by immunohistochemical staining was observed for Bcl-xL, Bcl-xs, or Bcl-2. However, in diseased skin samples that feature a prominent angiogenic response such as in psoriasis or pyogenic granulomas, the proliferating ECs markedly overexpressed Bcl-xL, with little to no Bcl-2. In an acquired-immune-deficiency-syndrome-related neoplasm, Kaposi's sarcoma, the spindle-shaped tumor cells also overexpressed Bcl-xL compared with Bcl-2. These in vivo studies were extended in vitro using cultured ECs and Kaposi's sarcoma tumor cells that were examined by flow cytometry and immunoblot analysis. Both cultured ECs and Kaposi's sarcoma tumor cells express significantly higher levels of Bcl-xL than Bcl-2. Such overexpression of cell survival gene products may contribute to prolonging the longevity of EC-derived cells in several different benign and neoplastic skin disorders that are characterized by a prominent angiogenic tissue response.
Indexed as
Identifiers
8780384PMC1865136W1876786158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.